Literature DB >> 10505009

Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population.

O Adekunle1, A Gopee, M el-Sayed, B Thilaganathan.   

Abstract

Although increased nuchal translucency (NT) has been linked to a wide range of fetal chromosomal abnormalities and genetic syndromes, very few studies have looked at the outcomes of chromosomally normal pregnancies in unselected obstetric populations. This study aims to evaluate the outcomes of pregnancies with nuchal translucency measurements greater than or equal to 4 mm in a low risk obstetric population attending for routine first trimester screening. Women attending for booking scans were routinely offered nuchal translucency measurement as a screening test for Down's syndrome between 10 and 14 weeks gestation. The prevalence of increased nuchal translucency was 0.8% (n = 53). There were 15 (28.3%) chromosomal abnormalities, the commonest of which was Down's syndrome. Of the 38 chromosomally normal pregnancies, seven resulted in intrauterine death, early neonatal death or termination of pregnancy. The remaining 31 cases resulted in livebirths, of which two infants now exhibit developmental delay of unknown aetiology and one has been diagnosed as having Noonan's syndrome. 10 (19%) pregnancies were diagnosed as having major anatomical malformations resulting in fetal or neonatal demise or requiring postnatal surgery. In a routine obstetric population, the finding of an NT measurement greater than or equal to 4 mm is associated with a poor pregnancy outcome in the majority of cases, mainly owing to chromosomal abnormality. This study establishes the need for focused fetal assessment in cases with such first trimester findings.

Entities:  

Mesh:

Year:  1999        PMID: 10505009     DOI: 10.1259/bjr.72.857.10505009

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  11 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Correlation between serum biochemical markers and early amniocentesis in diagnosis of congenital fetal anomalies.

Authors:  Dragan Loncar; Mirjana Varjacic; Tanja Novakovic; Dragan Milovanovic; Slobodan Jankovic
Journal:  Bosn J Basic Med Sci       Date:  2010-02       Impact factor: 3.363

3.  Long-term outcome of children born after a first-trimester measurement of nuchal translucency at the 99th percentile or greater with normal karyotype: a prospective study.

Authors:  Marie-Victoire Senat; Laurence Bussières; Sophie Couderc; Joelle Roume; Patrick Rozenberg; Jean Bouyer; Yves Ville
Journal:  Am J Obstet Gynecol       Date:  2007-01       Impact factor: 8.661

Review 4.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 5.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 6.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 7.  Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy.

Authors:  Laura Goetzl
Journal:  Clin Lab Med       Date:  2010-09       Impact factor: 1.935

Review 8.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 9.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

Review 10.  Noonan syndrome.

Authors:  Amy E Roberts; Judith E Allanson; Marco Tartaglia; Bruce D Gelb
Journal:  Lancet       Date:  2013-01-10       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.